C-CCWDsmall molecule GPCRs, structural biology, AI molecular design
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Develop an orally delivered small-molecule amylin agonist for obesity and other metabolic disorders.
Small-molecule drug discovery using structural biology, biophysical binding assays, AI-powered molecular design, medicinal chemistry, and high-throughput screening when needed.
Listed as an Ambrosia pipeline program; company announced a $100 million Series B financing on 2026-03-31.
Develop an orally delivered small-molecule GIP receptor antagonist for obesity and other metabolic disorders.
Small-molecule GPCR drug discovery using cryo-EM-enabled structural biology, biophysical binding assays, AI-powered molecular design, medicinal chemistry, and high-throughput screening when needed.
Listed as an Ambrosia pipeline program; company announced a $100 million Series B financing on 2026-03-31.
Develop an orally delivered small-molecule GLP-1 receptor agonist for obesity and other metabolic disorders with once-daily dosing.
Small-molecule GPCR drug discovery using cryo-EM-enabled structural biology, biophysical binding assays, AI-powered molecular design, medicinal chemistry, and high-throughput screening when needed.
Listed as an Ambrosia pipeline program; company announced a $100 million Series B financing on 2026-03-31.
Develop an orally delivered small-molecule GLP-1 receptor agonist for obesity and other metabolic disorders with once-weekly dosing.
Small-molecule GPCR drug discovery using cryo-EM-enabled structural biology, biophysical binding assays, AI-powered molecular design, medicinal chemistry, and high-throughput screening when needed.
Listed as an Ambrosia pipeline program; company announced a $100 million Series B financing on 2026-03-31.
Discover orally delivered small-molecule therapies for obesity and other metabolic disorders, including programs against GLP-1R, GIPR, and amylin.
Integrated platform combining cryo-EM-enabled structural biology, biophysical binding assays, AI-powered molecular design, medicinal chemistry, and high-throughput screening when needed.
Used to support Ambrosia's listed metabolic disease pipeline and associated with Series A financing announced on 2024-12-10 and Series B financing announced on 2026-03-31.